CA2201419C - Proteine de l'enveloppe du virus t-lymphotrope humain de type i et anticorps monoclonaux humains specifiques de cette proteine - Google Patents

Proteine de l'enveloppe du virus t-lymphotrope humain de type i et anticorps monoclonaux humains specifiques de cette proteine Download PDF

Info

Publication number: CA2201419C
Authority: CA; Canada
Prior art keywords: htlv; envelope protein; protein; envelope; human
Prior art date: 1996-04-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 2201419

Other languages

English (en)

Other versions

CA2201419A1 (fr

Inventor

Steven Kok Hing Foung

Gregory A. Dekaban

Jacqueline Arp

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Western Ontario

Leland Stanford Junior University

Original Assignee

University of Western Ontario

Leland Stanford Junior University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-02

Filing date

1997-04-01

Publication date

2005-07-12

1996-04-02 Priority claimed from US08/626,542 external-priority patent/US5722533A/en

1997-04-01 Application filed by University of Western Ontario, Leland Stanford Junior University filed Critical University of Western Ontario

1997-10-02 Publication of CA2201419A1 publication Critical patent/CA2201419A1/fr

2005-07-12 Application granted granted Critical

2005-07-12 Publication of CA2201419C publication Critical patent/CA2201419C/fr

2017-04-01 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

101710091045 Envelope protein Proteins 0.000 title claims abstract description 201
101710188315 Protein X Proteins 0.000 title claims abstract description 201
102100021696 Syncytin-1 Human genes 0.000 title claims abstract 43
241000714260 Human T-lymphotropic virus 1 Species 0.000 title abstract description 20
108090000623 proteins and genes Proteins 0.000 claims abstract description 73
102000004169 proteins and genes Human genes 0.000 claims abstract description 64
230000027455 binding Effects 0.000 claims abstract description 12
238000009739 binding Methods 0.000 claims abstract description 12
241001529934 Simian T-lymphotropic virus 3 Species 0.000 claims abstract description 8
241000714259 Human T-lymphotropic virus 2 Species 0.000 claims abstract 4
210000004027 cell Anatomy 0.000 claims description 97
241000700605 Viruses Species 0.000 claims description 38
239000000203 mixture Substances 0.000 claims description 31
239000002671 adjuvant Substances 0.000 claims description 26
230000002163 immunogen Effects 0.000 claims description 26
210000001744 T-lymphocyte Anatomy 0.000 claims description 19
238000000034 method Methods 0.000 claims description 17
210000004408 hybridoma Anatomy 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 12
210000003719 b-lymphocyte Anatomy 0.000 claims description 11
101100274557 Heterodera glycines CLE1 gene Proteins 0.000 claims description 10
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 8
238000009007 Diagnostic Kit Methods 0.000 claims description 7
230000017960 syncytium formation Effects 0.000 claims description 5
206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
238000010367 cloning Methods 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
230000003053 immunization Effects 0.000 claims description 2
201000000050 myeloid neoplasm Diseases 0.000 claims description 2
102000035122 glycosylated proteins Human genes 0.000 claims 1
108091005608 glycosylated proteins Proteins 0.000 claims 1
206010046865 Vaccinia virus infection Diseases 0.000 abstract description 30
208000007089 vaccinia Diseases 0.000 abstract description 30
208000015181 infectious disease Diseases 0.000 abstract description 25
230000009977 dual effect Effects 0.000 abstract description 22
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 abstract description 16
238000003745 diagnosis Methods 0.000 abstract description 4
102100034349 Integrase Human genes 0.000 description 164
235000018102 proteins Nutrition 0.000 description 52
101800000385 Transmembrane protein Proteins 0.000 description 33
230000014509 gene expression Effects 0.000 description 32
101800001271 Surface protein Proteins 0.000 description 29
229960005486 vaccine Drugs 0.000 description 26
239000000427 antigen Substances 0.000 description 21
102000036639 antigens Human genes 0.000 description 21
108091007433 antigens Proteins 0.000 description 21
208000006961 tropical spastic paraparesis Diseases 0.000 description 18
239000000523 sample Substances 0.000 description 17
241000700618 Vaccinia virus Species 0.000 description 16
241001430294 unidentified retrovirus Species 0.000 description 15
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 14
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 14
241000288906 Primates Species 0.000 description 12
230000028993 immune response Effects 0.000 description 12
230000029087 digestion Effects 0.000 description 11
230000003612 virological effect Effects 0.000 description 11
238000001262 western blot Methods 0.000 description 11
101900057918 Human T-cell leukemia virus 1 Surface protein Proteins 0.000 description 10
101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 10
239000013592 cell lysate Substances 0.000 description 10
238000010166 immunofluorescence Methods 0.000 description 10
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
239000012634 fragment Substances 0.000 description 9
229920001542 oligosaccharide Polymers 0.000 description 9
230000009257 reactivity Effects 0.000 description 9
239000000243 solution Substances 0.000 description 9
101710121417 Envelope glycoprotein Proteins 0.000 description 8
241000701044 Human gammaherpesvirus 4 Species 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 description 8
101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 description 8
YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 8
101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
230000003472 neutralizing effect Effects 0.000 description 8
150000002482 oligosaccharides Chemical class 0.000 description 8
ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 8
MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 8
241000282576 Pan paniscus Species 0.000 description 7
208000000389 T-cell leukemia Diseases 0.000 description 7
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
238000003556 assay Methods 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000003119 immunoblot Methods 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
208000030507 AIDS Diseases 0.000 description 6
241000598436 Human T-cell lymphotropic virus Species 0.000 description 6
230000004988 N-glycosylation Effects 0.000 description 6
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
230000013595 glycosylation Effects 0.000 description 6
238000006206 glycosylation reaction Methods 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
238000005406 washing Methods 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
208000030555 Pygmy Diseases 0.000 description 5
229940037003 alum Drugs 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
239000012133 immunoprecipitate Substances 0.000 description 5
238000001114 immunoprecipitation Methods 0.000 description 5
239000006166 lysate Substances 0.000 description 5
244000052769 pathogen Species 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 4
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
241000283707 Capra Species 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 4
241000701867 Enterobacteria phage T7 Species 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
102000003886 Glycoproteins Human genes 0.000 description 4
101001116388 Homo sapiens Melatonin-related receptor Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
201000006966 adult T-cell leukemia Diseases 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
239000011536 extraction buffer Substances 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
229920006008 lipopolysaccharide Polymers 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
229940126619 mouse monoclonal antibody Drugs 0.000 description 4
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000014616 translation Effects 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
241000710188 Encephalomyocarditis virus Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000024932 T cell mediated immunity Effects 0.000 description 3
101710120037 Toxin CcdB Proteins 0.000 description 3
206010044696 Tropical spastic paresis Diseases 0.000 description 3
238000007792 addition Methods 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
238000010276 construction Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
230000005745 host immune response Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000003308 immunostimulating effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
230000021633 leukocyte mediated immunity Effects 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
-1 octadecyl ester Chemical class 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
VHUVBWVDIFVVBI-SNYZSRNZSA-N (2s)-3-(4-hydroxyphenyl)-2-(octadecylamino)propanoic acid;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCCCCCN[C@H](C(O)=O)CC1=CC=C(O)C=C1 VHUVBWVDIFVVBI-SNYZSRNZSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
208000003322 Coinfection Diseases 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
229930186217 Glycolipid Natural products 0.000 description 2
229940121672 Glycosylation inhibitor Drugs 0.000 description 2
208000005599 HTLV-I Infections Diseases 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
108010034715 Light-Harvesting Protein Complexes Proteins 0.000 description 2
108010028921 Lipopeptides Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
241000282577 Pan troglodytes Species 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
108010060806 Photosystem II Protein Complex Proteins 0.000 description 2
241001466984 Simian T-lymphotropic virus 1 Species 0.000 description 2
101000913850 Tetrahymena thermophila Citrate synthase, mitochondrial Proteins 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 2
JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229930002868 chlorophyll a Natural products 0.000 description 2
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
229930002869 chlorophyll b Natural products 0.000 description 2
NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000003100 immobilizing effect Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000010185 immunofluorescence analysis Methods 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000001524 infective effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
235000009973 maize Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000019935 photoinhibition Effects 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000000163 radioactive labelling Methods 0.000 description 2
238000003156 radioimmunoprecipitation Methods 0.000 description 2
229930182490 saponin Natural products 0.000 description 2
150000007949 saponins Chemical class 0.000 description 2
235000017709 saponins Nutrition 0.000 description 2
235000020183 skimmed milk Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
XUJNEKJLAYXESH-XQSDEXCQSA-N (2r)-2-azanyl-3-sulfanyl-propanoic acid Chemical compound [35SH]C[C@H](N)C(O)=O XUJNEKJLAYXESH-XQSDEXCQSA-N 0.000 description 1
DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
101710118202 43 kDa protein Proteins 0.000 description 1
101710092702 47 kDa protein Proteins 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
208000036487 Arthropathies Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
101710102044 Envelope protein F13 homolog Proteins 0.000 description 1
101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010031186 Glycoside Hydrolases Proteins 0.000 description 1
102000005744 Glycoside Hydrolases Human genes 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
208000007687 HTLV-II Infections Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010022941 Iridocyclitis Diseases 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
239000012741 Laemmli sample buffer Substances 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028570 Myelopathy Diseases 0.000 description 1
101100129406 Neurospora africana MTA-1 gene Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000219061 Rheum Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000010530 Virus Neutralization Effects 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
239000012491 analyte Substances 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
201000004612 anterior uveitis Diseases 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
239000012620 biological material Substances 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
239000012568 clinical material Substances 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
230000005684 electric field Effects 0.000 description 1
238000001378 electrochemiluminescence detection Methods 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
108700004025 env Genes Proteins 0.000 description 1
101150030339 env gene Proteins 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000002339 glycosphingolipids Chemical class 0.000 description 1
ZYCMDWDFIQDPLP-UHFFFAOYSA-N hbr bromine Chemical compound Br.Br ZYCMDWDFIQDPLP-UHFFFAOYSA-N 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000001571 immunoadjuvant effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000000568 immunological adjuvant Substances 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
230000002621 immunoprecipitating effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
108010071397 lactoferrin receptors Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
241001515942 marmosets Species 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229940031346 monovalent vaccine Drugs 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
230000003571 opsonizing effect Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000005892 protein maturation Effects 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
238000012876 topography Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000010415 tropism Effects 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
239000013598 vector Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000001429 visible spectrum Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000002689 xenotransplantation Methods 0.000 description 1
238000004383 yellowing Methods 0.000 description 1
UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
229940007718 zinc hydroxide Drugs 0.000 description 1
229910021511 zinc hydroxide Inorganic materials 0.000 description 1

Landscapes

Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA 2201419 1996-04-02 1997-04-01 Proteine de l'enveloppe du virus t-lymphotrope humain de type i et anticorps monoclonaux humains specifiques de cette proteine Expired - Fee Related CA2201419C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/626,542		1996-04-02
US08/626,542 US5722533A (en)	1995-11-30	1996-04-02	Device exerting a protective action against fluid seepages in electrical switches and the like

Publications (2)

Publication Number	Publication Date
CA2201419A1 CA2201419A1 (fr)	1997-10-02
CA2201419C true CA2201419C (fr)	2005-07-12

Family

ID=24510834

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2201419 Expired - Fee Related CA2201419C (fr)	1996-04-02	1997-04-01	Proteine de l'enveloppe du virus t-lymphotrope humain de type i et anticorps monoclonaux humains specifiques de cette proteine

Country Status (1)

Country	Link
CA (1)	CA2201419C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN118598971A (zh) *	2024-07-01	2024-09-06	华南农业大学	一种猪izumo2真核蛋白及其单克隆抗体的制备方法和应用

1997
- 1997-04-01 CA CA 2201419 patent/CA2201419C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2201419A1 (fr)	1997-10-02

Legal Events

Date	Code	Title	Description
2001-12-19	EEER	Examination request
2015-05-13	MKLA	Lapsed	Effective date: 20150401

Publication	Publication Date	Title
Tilley et al.	1991	A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity
US5643756A (en)	1997-07-01	Fusion glycoproteins
Arthur et al.	1989	Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120
Griffiths et al.	1993	Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag: V3 fusion
AU632475B2 (en)	1993-01-07	Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5580773A (en)	1996-12-03	Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
Ikuta et al.	1989	Expression of human immunodeficiency virus type 1 (HIV-1) gag antigens on the surface of a cell line persistently infected with HIV-1 that highly expresses HIV-1 antigens
US5166050A (en)	1992-11-24	Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
Giavedoni et al.	1993	Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection
Losman et al.	2001	Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region
US7847085B2 (en)	2010-12-07	Recombinant HIV-1 gp120 immunogen with three different V3 loops from viruses of different clades
IE872219L (en)	1988-02-20	Treatment of hiv infections
Schlienger et al.	1992	Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates
KR100482616B1 (ko)	2005-09-02	다수-서브타입fiv백신
KR0172970B1 (ko)	1999-02-01	Aids백신에 유용한 키메릭 단백 및 그의 제조방법
Durda et al.	1990	HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide
Hourioux et al.	2000	Identification of the Glycoprotein 41™ Cytoplasmic Tail Domains of Human Immunodeficiency Virus Type 1 That Interact with Pr55Gag Particles
Torres et al.	1993	An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation
Matsushita et al.	1995	Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120
Kalyan et al.	1994	Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1
Arp et al.	1996	A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system
Radaelli et al.	1994	Expression of HIV-1 envelope gene by recombinant avipox viruses
CA2201419C (fr)	2005-07-12	Proteine de l'enveloppe du virus t-lymphotrope humain de type i et anticorps monoclonaux humains specifiques de cette proteine
US5961984A (en)	1999-10-05	Human T-cell lymphotropic virus type I envelope protein and human monoclonal antibodies specific therefor
Bugge et al.	1990	Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody